StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 12, 2026, 04:15 PM

Acrivon Q2 Net Loss $(17.96)M; Raises $7.3M via ATM Offering

AI Summary

Acrivon Therapeutics reported a reduced net loss of $(17.96) million for the second quarter of 2026, an improvement from $(21.01) million in the prior year. Total operating expenses also decreased, contributing to a lower net loss of $(37.01) million for the first half of 2026. The company strengthened its financial position by raising $7.3 million through an 'at-the-market' offering, and expects its $90.0 million in cash, cash equivalents, and investments to fund operations for at least 12 months, despite an accumulated deficit of $(311.89) million.

Key Highlights

  • Net loss for Q2 2026 was $(17.96) million, down from $(21.01) million in Q2 2025.
  • Net loss for H1 2026 was $(37.01) million, compared to $(40.69) million in H1 2025.
  • Total operating expenses for Q2 2026 decreased to $18.67 million from $22.65 million.
  • Cash, cash equivalents, and investments totaled $90.0 million as of June 30, 2026.
  • Raised $7.3 million gross proceeds from an 'at-the-market' offering in April 2026.
  • Existing liquidity is expected to fund operations for at least 12 months.
  • Accumulated deficit reached $(311.89) million as of June 30, 2026.